Swiss National Bank
EWTX icon

Swiss National Bank’s Edgewise Therapeutics EWTX Stock Holding History

Swiss National Bank’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.27M Hold
103,900
– – ﹤0.01% 1588
2025
Q4 		$2.58M Buy
103,900
+2,000
+2% +$40.1K ﹤0.01% 1740
2025
Q3 		$1.65M Buy
101,900
+11,900
+13% +$169K ﹤0.01% 1941
2025
Q2 		$1.18M Buy
90,000
+7,400
+9% +$107K ﹤0.01% 2068
2025
Q1 		$1.82M Buy
82,600
+9,000
+12% +$236K ﹤0.01% 1821
2024
Q4 		$1.97M Hold
73,600
– – ﹤0.01% 1866
2024
Q3 		$1.96M Hold
73,600
– – ﹤0.01% 1869
2024
Q2 		$1.33M Buy
73,600
+6,300
+9% +$110K ﹤0.01% 2028
2024
Q1 		$1.23M Buy
67,300
+17,200
+34% +$273K ﹤0.01% 2115
2023
Q4 		$548K Buy
+50,100
New +$352K ﹤0.01% 2455

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Swiss National Bank's EWTX Position: Q1 2026 in Review

Swiss National Bank held its Edgewise Therapeutics (EWTX) position steady in Q1 2026 at 103,900 shares worth $3.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1588.

Swiss National Bank first reported a position in EWTX in Q4 2023 and has held it in 10 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Swiss National Bank held 103,900 shares of Edgewise Therapeutics worth $3.27M as of Q1 2026.
  • Swiss National Bank left its Edgewise Therapeutics share count unchanged in Q1 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1588 holding.
  • Swiss National Bank first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.